The Patent Finder

Genethon

19 patents currently held · Updated Nov 18, 2026
23 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

3
Ending by 2030
Jul 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 26, 2027
    The maintenance fee for Widespread Gene Delivery to Motor Neurons Using Peripheral Injection of Aav Vectors (US 11,767,538) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
  • 3 fees due May 5 to 21, 2027 · next May 5

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026
  • 2 terms have ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,208,318CNS Gene Delivery Using Peripheral Administration of Aav Vectors
In force
 · High confidence
In forceHigh confidence
US 11,767,538Widespread Gene Delivery to Motor Neurons Using Peripheral Injection of Aav Vectors
In force
 · High confidence
In forceHigh confidence
US 12,351,816CNS Gene Delivery Using Peripheral Administration of Aav Vectors
In force
 · Medium confidence
In forceMedium confidence
US 9,526,742Use of epigenome-modifying compounds for the treatment of genetic muscular diseases linked to a protein-conformational disorder
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,933,438Method for diagnosing muscular dystrophy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,957,044Systemic Gene Replacement Therapy for Treatment of X-Linked MyoTubular Myopathy (XLMTM)
In force
 · High confidence
In forceHigh confidence
US 9,415,120Systemic Gene Replacement Therapy for Treatment of X-Linked Myotubular Myopathy (XLMTM)
In force
 · High confidence
In forceHigh confidence
US 9,839,677Systemic Gene Replacement Therapy for Treatment of X-Linked Myotubular Myopathy (XLMTM)
In force
 · High confidence
In forceHigh confidence
US 9,895,426Systemic Gene Replacement Therapy for Treatment of X-Linked Myotubular Myopathy (XLMTM)
In force
 · High confidence
In forceHigh confidence
US 11,564,977Systemic Gene Replacement Therapy for Treatment of X-Linked Myotubular Myopathy (XLMTM)
In force
 · High confidence
In forceHigh confidence
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 23 patents in force now held by others · 19 lapsed for an unpaid fee · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

27 pending · 30 abandoned · 6 no status recorded

Showing 1 to 10 of 63, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
19/258,034CNS Gene Delivery Using Peripheral Administration of Aav VectorsJul 2, 2025Pending
19/208,730Acid-Alpha Glucosidase Variants and Uses ThereofMay 15, 2025Pending
18/991,814Hybrid Regulatory ElementsDec 23, 2024Pending
18/808,144Fluidic System for Producing Extracellular Vesicles and Related MethodAug 19, 2024Pending
18/735,636Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver TropismJun 6, 2024Pending
18/339,842Treatment of HyperbilirubinemiaJun 22, 2023Pending
18/058,283Acid-Alpha Glucosidase Variants and Uses ThereofNov 23, 2022Abandoned
18/049,296Treatment of Glycogen Storage Disease IIIOct 25, 2022Abandoned
17/929,816Stable Pseudotyped Lentiviral Particles and Uses ThereofSep 6, 2022Pending
18/294,577Hybrid Promoters for Gene Expression in Muscles and in the CNSAug 4, 2022Pending
10 of 63 applications shown.
Pro members see all 63 published applications.
Pro members: see all 63 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited